Comparison of Receptor Mechanisms and Efficacy Requirements for δ-Agonist-Induced Convulsive Activity and Antinociception in Mice
- 1 January 2002
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (2) , 723-729
- https://doi.org/10.1124/jpet.102.036525
Abstract
δ-Opioid receptor-selective agonists produce antinociception and convulsions in several species, including mice. This article examines two hypotheses in mice: 1) that antinociception and convulsive activity are mediated through the same type of δ-receptor and 2) that greater δ-agonist efficacy is required for antinociception than for convulsive activity. δ-Mediated antinociception was evaluated in the acetic acid-induced abdominal constriction assay, which involves a low-intensity noxious stimulus; convulsive activity was indicated as a mild tonic-clonic convulsive episode followed by a period of catalepsy. In δ-opioid receptor knockout mice [DOR-1(−/−)], the nonpeptidic δ-agonists (±)-4-[(R*)-[(2S*,5R*)-2,5-dimethyl-4-(2-propenyl)-1- piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide hydrochloride (BW373U86) and (+)-4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N, N-diethylbenzamide (SNC80) failed to produce convulsive behavior demonstrating the absolute involvement of DOR-1 in this effect. In NIH Swiss mice expressing δ-opioid receptors, BW373U86 produced both antinociception and convulsive activity. These effects were antagonized by the putative δ1-receptor-selective antagonist 7-benzylidenenaltrexone and the putative δ2-receptor-selective antagonist naltriben. Tolerance developed to both the convulsive and antinociceptive effects of BW373U86. Tolerance to the convulsive, but not the antinociceptive, effects of BW373U86 was largely prevented when the antagonist naltrindole was given 20 min after each dose of the agonist in a 3-day treatment paradigm. The convulsive action of BW373U86 was also less sensitive than the antinociceptive action to treatment with the irreversible δ-antagonist naltrindole isothiocyanate. Collectively, these data suggest that the convulsive and antinociceptive activities of δ-agonists are mediated through the same receptor but that the receptor reserve for δ-mediated convulsive activity is greater than for δ-mediated antinociceptive activity.Keywords
This publication has 18 references indexed in Scilit:
- Oligomerization of μ- and δ-Opioid ReceptorsJournal of Biological Chemistry, 2000
- Antihyperalgesic effects of δ opioid agonists in a rat model of chronic inflammationBritish Journal of Pharmacology, 2000
- A comparison of the anti‐inflammatory and anti‐nociceptive activity of nitroaspirin and aspirinBritish Journal of Pharmacology, 2000
- Constitutive activity of the δ‐opioid receptor expressed in C6 glioma cells: identification of non‐peptide δ‐inverse agonistsBritish Journal of Pharmacology, 1999
- Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout MiceNeuron, 1999
- Differential effects of chylomicron remnants derived from corn oil or palm oil on bile acid synthesis and very low density lipoprotein secretion in cultured rat hepatocytesLife Sciences, 1996
- Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of (+)-4-[(.alpha.R)-.alpha.-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide .delta. Opioid Receptor AgonistJournal of Medicinal Chemistry, 1994
- Differential antagonism by naltrindole-5′-isothiocyanate on [3H]DSLET and [3H]DPDPE binding to striatal slices of miceLife Sciences, 1993
- .delta. Opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for .delta. receptor subtypesJournal of Medicinal Chemistry, 1992
- Naltrindole-5'-isothiocyanate: a nonequilibrium, highly selective .delta.-opioid receptor antagonistJournal of Medicinal Chemistry, 1990